http://www.anp4all.com Part 2: like Cheese from the University of Wisconsin, Eau Claire, only more so?

CHEEZ WHIZ !!! http://anp4all.com is nothing more than Robert J. “Bob” Blaskiewicz (@rjblaskiewicz)’s thick processed cheese spread of http://thehoustoncancerquack.com
======================================
Where he asks:

DO YOU THINK YOU HAVE AN OPEN MIND? DO YOU HAVE THE ALL THE FACTS?
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/04/18/fact-checking-httpthehoustoncancerquack-com/
======================================
He is supposedly a “Professor of Writing”, but check out his writing gaffes here, as “ANONYMOUS”
======================================
Yes! Weekly: Burzynski: Cancer is Serious Business Part II:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/08/26/yes-weekly-burzynski-cancer-is-serious-business-part-ii/
======================================
Critiquing https://theotherburzynskipatientgroup.wordpress.com
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/08/24/critiquing-httpstheotherburzynskipatientgroup-wordpress-com/
======================================
“The skeptic who called Dr. Burzynski “my little Polish sausage” has a Polish last name, which the director Eric Merola scrubbed from the movie”

Just because you think that referring to someone as:

“my little Polish sausage”

is humorous, and therefor we should excuse your behavior because of your below excuse, does NOT mean that it makes it acceptable

“Literally one second after he said that, all of the other participants made jokes about that fact”

(which of course was the point)

“Instead allowing the audience to hear that ribbing, Merola inserted an evil laugh, which was lifted and spliced from minute 18:25 of Virtual Skeptics episode 13”

If you thought that was an “evil laugh”, you’ve got an overactive imagination

“Voices were altered to sound sinister, and menacing music was added”

If you thought voices sounded “sinister” and that was “menacing music”, you must not watch any scary movies

Do you think this is a fair representation or were you misled?

YES

I think it’s a fair representation that you try to mislead people

“What about the 2-hour rejection from The Lancet?”

“High impact journals like The Lancet receive huge numbers of submissions, as their journal is the most prestigious”

“The vast majority of papers that get rejected by The Lancet are rejected within 48 hours thanks to an editorial pre-screening process that helps accommodate this huge work load”

“Most researchers are thankful for this courtesy because it allows them to resubmit to other journals more quickly”

“Why does Merola try to convince the audience that this is evidence of a conspiracy against Burzynski?”

All of your above comments prove what a waste of time you are, based on:
======================================
See #13
——————————————————————
Critiquing: In which the latest movie about Stanislaw Burzynski “cancer cure” is reviewed…with Insolence:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/07/18/critiquing-in-which-the-latest-movie-about-stanislaw-burzynski-cancer-cure-is-reviewed-with-insolence-2/
======================================
2 hours 8 minutes and 51 seconds
The Lancet Oncology Peer Review Team D-12-01519: #FAIL

——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/07/25/the-lancet-oncology-peer-review-team-d-12-01519-fail/
======================================
“Does Eric Merola have any conflicts of interest that he is not disclosing?”

“Eric Merola does not reveal a possible conflict of interest, one that a journalist would feel obliged to share”

“He fails to disclose in the movie that his cousin was a patient of Dr. Burzynski and that he has raised money on his movie’s website for patients to see Burzynski”

Sounds like someone failed to read the Frequently Asked Questions (FAQ) section on the BurzynskiMovie web-site:
======================================
http://burzynskimovie.com/index.php?option=com_content&view=article&id=75&Itemid=55
======================================
“Burzynski has never published the results of those trials but keeps the money:”

“Burzynski’s abysmal trial completion record, over sixty abandoned trials, the trust of every patient who participated betrayed”

“If trial completion were a batting average, he’d be batting .016”

“His publication average is .000.”

“Really:”
——————————————————————
http://clinicaltrials.gov/ct2/results?term=burzynski&pg=1
——————————————————————
Really ?

“over sixty abandoned trials” ?

This just shows that you do NOT even know the subject-matter

Have you even bothered to read Burzynski’s publications ?
======================================
Burzynski updates Scientific Publications page:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/03/12/burzynski-updates-scientific-publications-page/
======================================
Because if you had, you would know that Burzynski has used the clinical trial design proposed by Fleming
======================================
16. 2003 Trial design – Fleming (Pg. 94)
——————————————————————
17. 2004 Trial design – Fleming (Pg. 317)
======================================
Protocol Design

2-stage phase II clinical trial design proposed by Fleming used

Initially, 20 adequately treated patients to be assessed

If less than one Objective Response (Complete Response (CR) or Partial Response (PR)) observed, it’d be concluded there was less than desired activity and study would be discontinued

If one or more Objective Responses observed, 20 more patients would be accrued to study

If 4 or more responses observed among 40 patients, evidence would be sufficient to conclude the treatment has desired activity
======================================
One-sample multiple testing procedure for phase II clinical trials
http://www.ncbi.nlm.nih.gov/pubmed/7082756/
Journal
Biometrics. 1982 Mar;38(1):143-51
http://www.ncbi.nlm.nih.gov/m/pubmed/7082756/

http://www.jstor.org/discover/10.2307/2530297?uid=3739256&uid=2460338175&uid=2460337855&uid=2&uid=4&uid=83&uid=63&sid=21102589296903
======================================
Obviously, it took time to accrue the number of patients who fit the specific protocol criteria to complete the study, and you would NOT publish the final results until all the data was compiled

“Speaking of harassment…”

“Merola does not mention that skeptics only caught wind of the Burzynski story in November 2011, after a teenaged blogger critical of the Clinic received phony legal threats from someone who had been hired by the Clinic to “clean up” its reputation”

Poor Welsh schoolboy Rhys Morgan

Where did he get the information for his blog ?

From other bloggers ?

Because I could NOT see any indication that he did any “real” research

And when I attempted to post a comment to his blog, he turned out to be a coward, like so many of The Skeptics™
======================================
http://rhysmorgan.co/burzynski-morally-reprehensible/#comment-5179
Didymus Judas Thomas

April 1, 2013 at 5:19 am # 51

1. Burzynski does NOT charge for antineoplastons

2. Burzynski has had “Independent” sources in Kurume, Japan complete a Randomized Phase II Clinical Trial study utilizing antineoplastons that doubled the 5-year survival rate of cancer patients

3. You do know that the Declaration of Helsinki does NOT require Burzynski to publish when YOU think he “ethically” should, right?
http://www.wma.net/en/30publications/10policies/b3
Your comment is awaiting moderation

50 Comments
↓
======================================
“This person, Marc Stephens, sent this high school student images of his family’s home, the message clearly:”

“We know where you live.”

“These threats were well documented in the international press”

“Somehow Merola managed to not mention that in the movie”

Yes

Marc Stephens’ actions were idiotic

My personal opinion is that he should have done what I am doing, which is showing how “The Skeptics™ lie, misinform, disinform, misdirect, deceive, misrepresent, etc.

Eric Merola did NOT mention your lame blogs either

Why don’t you complain about that ?

“Burzynski has a long history of patients believing that symptoms of getting worse are signs they are getting better”

“Follow any of the links at that site to hear how, in patients’ own words, this EXACT SAME misleading interpretation has been fed to patients for decades”

So, are you a doctor ?

No ?

I didn’t think so, quack

“Merola has publicly slandered Burzynski critics in a way a real journalist couldn’t”

Why can “real journalists” NOT slander someone ?

“We hope this makes it clear that what you are seeing in the new Burzynski movie may not be entirely reliable”

So, like this web-site ?
======================================
The Burzynski Skeptics:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/08/18/the-burzynski-skeptics/
======================================
The #Burzynski Skeptics™ are SkeptiScared:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/08/12/3666/
======================================
“The Skeptics” (Burzynski: Cancer is Serious Business, Part II):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/03/24/the-skeptics/
======================================
The Skeptics Theme Song:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/05/25/the-skeptics-theme-song/
======================================
The #Burzynski (B.S.) Bump Rap:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/06/06/the-burzynski-b-s-bump-rap/
======================================

Critiquing https://theotherburzynskipatientgroup.wordpress.com

Critiquing https://theotherburzynskipatientgroup.wordpress.com

Robert J. (Bob) Blaskiewicz operates The Other Burzynski Patient Group (TOBPG)

The problem is:

1. Bob Blaskiewicz Faux Skeptic Exposed! does NOT want to debate or want people to consider the failures of Science Based Medicine compared to Burzynski, because he has an agenda

2. @rjblaskiewicz is a known LIAR

Making unsubstantiated claims like this:

Bob Blaskiewicz (@rjblaskiewicz) tweeted at 9:45am – 25 Aug 13:

@dixon_frederick @AlaaTheWarrior Actually, he CLAIMS a success rate, but is unable to publish. Suspicious: clinicaltrials.gov/ct2/results?te…

https://twitter.com/rjblaskiewicz/status/371644524809842690
� � � � � � � � � � � � � � � � �
374 – TOTAL CHILDREN DIED:
Science Based Medicine

� � � � � � � � � � � � � � � � �
======================================
[6] .9/15/1999 – 29 / 85% died
======================================
[9] .9/15/1994 – 51 / 88% – children died
======================================
[8] 1/1998 – 8 / 89% of 9 children died of their disease at median of 44 weeks
======================================
[5] .10/21/2002 – 12 / 100% – all children patients died
======================================
[2] 5/1/2010 – 18 – children patients have died from disease progression
======================================
[3] 2/2008 – All 30 / 100% – children have died
======================================
[4] 1/1/2005 – 33 / 100% – children died of disease progression
======================================
[1] 4/2011 – 63 / 100% – children died
======================================
[7] .3/15/1999 – 130 / 100% – children died
======================================
� � � � � � � � � � � � � � � � �
======================================
COMBINED:
======================================
� � � � � � � � � � � � � � � � �
======================================
[1] 4/2011 – children with newly diagnosed diffuse intrinsic pontine glioma (DIPG)
——————————————————————
[1] 4/2011 – children with DIPG
——————————————————————
[1] 5/1/2010 children with newly diagnosed diffuse intrinsic pontine glioma
——————————————————————
[1] 5/1/2010 children with diffuse intrinsic pontine gliomas (DIPGs)
——————————————————————
[1] 5/1/2010 Pediatric patients with newly diagnosed DIPGs
——————————————————————
[3] 2/2008 – children with diffuse intrinsic brain stem glioma
——————————————————————
[3] 2/2008 – diffuse intrinsic pontine glioma
——————————————————————
[4] 1/1/2005 – newly diagnosed diffuse brainstem glioma in children
——————————————————————
[4] 1/1/2005 – children with newly diagnosed diffuse brainstem glioma
——————————————————————
[4] 1/1/2005 – newly diagnosed, diffuse, intrinsic brain stem glioma
——————————————————————
[5] .10/21/2002 – typical diffuse pontine glioma
or
histologically proven anaplastic astrocytoma/glioblastoma multiforme located in the pons

——————————————————————
[5] .10/21/2002 – pontine glioma patients
——————————————————————
[5] .10/21/2002 – paediatric patients with pontine gliomas
——————————————————————
[5] .10/21/2002
brain tumours
brain stem glioma

——————————————————————
[5] .10/21/2002
Histological diagnoses included

8 – glioblastoma multiforme
5 – no histology
3 – anaplastic astrocytoma
3 – astrocytoma with no other specification
1 – pilocytic astrocytoma

——————————————————————
[6] .9/15/1999 – Brainstem gliomas
——————————————————————
[6] .9/15/1999 – diffuse intrinsic pontine tumor
——————————————————————
[6] .9/15/1999 – high grade glioma was required for nonpontine brain stem tumors
——————————————————————
[7] .3/15/1999 children with newly diagnosed brainstem tumor
——————————————————————
[7] .3/15/1999 tumors arising in the pons
——————————————————————
[7] .3/15/1999 diffusely infiltrating pontine lesion
——————————————————————
[8] 1/1998 – children with diffuse pontine gliomas
——————————————————————
[8] 1/1998 – pediatric malignancies
——————————————————————
[8] 1/1998 – Diffuse pontine gliomas
——————————————————————
[9] .9/15/1994 – Brain stem gliomas
——————————————————————
[9] .9/15/1994 – childhood brain tumors
——————————————————————
[9] .9/15/1994 – children with brain stem gliomas
——————————————————————
[9] .9/15/1994 – patients with diffuse intrinsic brain stem gliomas
——————————————————————
[9] .9/15/1994 – children with diffuse intrinsic brain stem gliomas
======================================
� � � � � � � � � � � � � � � � �
======================================
# OF CHILDREN
======================================
� � � � � � � � � � � � � � � � �
======================================
[8] 1/1998 – 9 / 100% – consecutive children
——————————————————————
[5] .10/21/2002 – 20 – enrolled (9 male / 11 female)
——————————————————————
[2] 5/1/2010 – 20 – children accrued
——————————————————————
[3] 2/2008 – 31 – children enrolled
——————————————————————
[4] 1/1/2005 – 33 / 100% – patients enrolled
——————————————————————
[6] .9/15/1999 – 34 / 100% – patients enrolled
——————————————————————
[1] 4/2011 – 63 / 100% – children enrolled in study
——————————————————————
[9] .9/15/1994 – 66 children
——————————————————————
[7] .3/15/1999
130 – eligible patients
66 – arm 1
64 – arm 2
======================================
� � � � � � � � � � � � � � � � �
======================================
# OF EVALUABLE CHILDREN
======================================
� � � � � � � � � � � � � � � � �
======================================
[8] 1/1998 – 9 / 100% – consecutive children evaluable
——————————————————————
[5] .10/21/2002 – 12 – Evaluable patients
——————————————————————
[2] 5/1/2010 – 20 – children evaluable
——————————————————————
[3] 2/2008 – 30 – eligible and evaluable for survival and toxicity
——————————————————————
[4] 1/1/2005 – 33 / 100% – patients evaluable
——————————————————————
[6] .9/15/1999 – 34 / 100% – patients evaluable
——————————————————————
[9] .9/15/1994 – 58 / 100% – evaluable patients
——————————————————————
[1] 4/2011 – 63 / 100% – children evaluable
——————————————————————
[7] .3/15/1999
130 – evaluable patients
66 – arm 1
64 – arm 2
======================================
� � � � � � � � � � � � � � � � �
======================================
AGE RANGE OF CHILDREN
======================================
� � � � � � � � � � � � � � � � �
======================================
[5] .10/21/2002 – 3-17 years of age
——————————————————————
[6] .9/15/1999 – 3.6–15.4 years
——————————————————————
[3] 2/2008 – 3–21 – age children enrolled
——————————————————————
[4] 1/1/2005 – 3-21 years – eligible for current multiinstitutional study
——————————————————————
[7] .3/15/1999 3-21 years of age
======================================
� � � � � � � � � � � � � � � � �
======================================
MEDIAN AGE OF CHILDREN
======================================
� � � � � � � � � � � � � � � � �
======================================
[5] .10/21/2002 – 6 years – median age
——————————————————————
[4] 1/1/2005 – 6.4 years – Median age at diagnosis
——————————————————————
[9] .9/15/1994 – 7.5 years – mean age at diagnosis
——————————————————————
[6] .9/15/1999 – 7.8 years – median age of patients
——————————————————————
[3] 2/2008 – 8 – median age (3–14 years)
——————————————————————
[2] 5/1/2010 – 8.3 years – mean age
======================================
� � � � � � � � � � � � � � � � �
======================================
1 YEAR OR LESS SURVIVAL RATES
======================================
� � � � � � � � � � � � � � � � �
======================================
[1] 4/2011 – 9 / 14% – mean 1-year Event-Free Survival (EFS)
——————————————————————
[1] 4/2011 – 14 / 21.9% – no evidence produced 1-year Event-Free Survival (EFS) rate higher than
——————————————————————
10/2006..5 / 26% – 1 year: Burzynski Antineoplastons: Progression-Free Survival Rate (PFS): Protocol – BT-11 BRAINSTEM GLIOMAS and multicentric tumors (MBSG) (Pg. 466)
——————————————————————
[7] 3/15/1999 – 17 / 27.0% – ARM 2: 1 year Patients Surviving: Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
——————————————————————
10/2004..9 / 29% – Burzynski Antineoplastons: 1 year Progression-Free Survival (PFS): Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG): Special Exception (SE) (Pg. 386)
——————————————————————
[7] 3/15/1999 – 40 / 30.9% – ARM 1: 1 year Patients Surviving: Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
——————————————————————
[9] .9/15/1994 – 20 / 35% – 1 year Overall Survival
——————————————————————
3/2006..39% – Burzynski Antineoplastons Patients with high-grade, recurrent and progressive BRAINSTEM GLIOMAS: Progression-Free Survival (PFS) at 6 months: BRAINSTEM GLIOMA (BSG) (Pgs. 40 + 44-45)
——————————————————————
[1] 4/2011 – 25 / 40% – mean 1-year Overall Survival (OS)
——————————————————————
10/2004..12 / 41% – Burzynski l: 1 year Progression-Free Survival (PFS): Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG) (Pg. 386)
——————————————————————
3/2004 – 43% – Burzynski Antineoplastons – % of responding Patients didn’t develop Progression: 6/1/2003 Protocol – BT-11 – BRAIN STEM GLIOMA (Pg. 51)
——————————————————————
[4] 1/1/2005 – 16 / 48% – 1 year estimated Survival rate
——————————————————————
10/2006..10 / 53% – Burzynski Antineoplastons 1 year Overall Survival Rate (OS): Protocol – BT-11 BRAINSTEM GLIOMAS and multicentric tumors (MBSG) (Pg. 466)
——————————————————————
3/2004 – 61% – Burzynski Antineoplastons % of Objective Response (OR) Patients hadn’t had Progression: 6/1/2003 Protocol – HIGH-GRADE GLIOMA (Pg. 53)
——————————————————————
[3] 2/2008 – 27 / 90% – 1 year  - Overall survival
======================================
� � � � � � � � � � � � � � � � �
======================================
LESS THAN 1 YEAR SURVIVAL (MST)
======================================
� � � � � � � � � � � � � � � � �
======================================
[7] 3/15/1999 – 5 months – ARM 2: Median time to Disease Progression: Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
——————————————————————
3/2006.-.6 months – Patients with Recurrent Tumors Survive no more than, despite standard treatment: (Pgs. 40 + 45-46)
——————————————————————
[7] 3/15/1999 – 6 months – ARM 1: Median time to Disease Progression: Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
——————————————————————
2003 – 6.4 months – Burzynski Antineoplastons Median Survival: Protocol patients with recurrent diffuse intrinsic BRAIN STEM GLIOMA: BT-11 Special Exception (SE) (Pg. 99)
——————————————————————
2003 – 7 months – Burzynski Antineoplastons Median Survival: Protocol patients with recurrent diffuse intrinsic BRAIN STEM GLIOMA: BT-11 (Pg. 99)
——————————————————————
3/2004 – 7 months – Burzynski Antineoplastons – Progression-Free Survival (PFS): 6/1/2003 Protocol – BT-11 BRAIN STEM GLIOMA (Pg. 51)
——————————————————————
3/2004 – 7 months – Burzynski Antineoplastons Progression-Free Survival (PFS): Protocol – subgroup very difficult to treat recurrent diffuse intrinsic BRAIN STEM GLIOMA (Pg. 52)
——————————————————————
[7] 3/15/1999 – 8 months – ARM 2: Median time to Death: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992 – 10/1997) 2004 (Pg. 58)
——————————————————————
[7] 3/15/1999 – 8 months – ARM 2: Median Overall Survival from Diagnosis (OSD): Median time to Death: Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
——————————————————————
[7] 3/15/1999 – 8 months – ARM 2: Median Overall Survival from start of Treatment (OST): Median time to Death: Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
——————————————————————
[7] 3/15/1999 – 8.5 months – Median Survival (MST): standard radiation therapy in combination with chemotherapy (RAT) (Mandell et al.) (6/1992–10/1997) children with newly diagnosed diffuse intrinsic BRAIN STEM TUMORS: results of pediatric oncology group
——————————————————————
[7] 3/15/1999 – 8.5 months – ARM 1: Median Overall Survival from start of Treatment (OST): Median time to Death: Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
——————————————————————
[7] 3/15/1999 – 8.5 months – ARM 1: Median time to Death: Median Overall Survival from Diagnosis (OSD): Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
——————————————————————
3/2004 – 10.3 months – Burzynski Antineoplastons – Median Overall Survival from start of Treatment (OST): 6/1/2003 Protocol – BT-11 BRAIN STEM GLIOMA (Pg. 51)
======================================
� � � � � � � � � � � � � � � � �
======================================
1 YEAR SURVIVAL
======================================
� � � � � � � � � � � � � � � � �
======================================
3/2004 – 12 months (1 year) – Burzynski Antineoplastons: Progression-Free Survival (PFS): 6/1/2003 Protocol – HIGH-GRADE GLIOMA (Pg. 53)
======================================
� � � � � � � � � � � � � � � � �
======================================
1+ YEAR SURVIVAL
======================================
� � � � � � � � � � � � � � � � �
======================================
3/2004 – 13.7 months (1 year 1.7 months) – Burzynski Antineoplastons: Median Overall Survival from Diagnosis (OSD): 6/1/2003 Protocol – BT-11 BRAIN STEM GLIOMA (Pg. 51)
——————————————————————
4/2007 – 16.4 months (1 year 4.4 months) – Burzynski Antineoplastons(ANP): Median Survival (MST): Protocol – newly diagnosed diffuse, intrinsic BRAINSTEM GLIOMAs (NDBSG) BT-11 (Pg. 206)
——————————————————————
3/2004 – 17 months (1 year 5 months) – Median Survival without Treatment (Pg. 53)
——————————————————————
2006 – 19.9 months (1 year 7.9 months) – Median Survival Time (MST): next best traditional standard of care study (Pg. 172)
——————————————————————
2006 – 19.9 months (1 year 7.9 months) – Burzynski Antineoplastons (ANP): Median Survival Time (MST): Treatments for Astrocytic Tumors – recurrent and progressive tumor: Treatment of diffuse, intrinsic BRAINSTEM GLIOMA in children (Pg. 172)
======================================
� � � � � � � � � � � � � � � � �
======================================
2 YEAR SURVIVAL
======================================
� � � � � � � � � � � � � � � � �
======================================
3/2006 – 2 years – Most Patients with BRAINSTEM GLIOMA fail standard radiation therapy and chemotherapy and don’t survive longer: (Pgs. 40 + 45-46)
——————————————————————
[7] 3/15/1999 – 4 / 6.7% – ARM 2: 2 year Patients Surviving: Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
——————————————————————
[7] 3/15/1999 – 7% – 2 year Overall Survival (OS): standard radiation therapy in combination with chemotherapy (RAT) (Mandell et al.) (6/1992–10/1997) children with newly diagnosed diffuse intrinsic BRAIN STEM TUMORS: results of pediatric oncology group
——————————————————————
[7] 3/15/1999 – 9 / 7.1% – ARM 1: 2 year Patients Surviving: Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
——————————————————————
Less than 10% – 2 year Survival: standard radiation therapy: for newly diagnosed diffuse intrinsic BRAIN STEM GLIOMA (DBSG)
——————————————————————
[3] 2/2008 – 3 / 10% – 2 years – Overall survival
——————————————————————
10/2006..3 / 16% – 2 years: Burzynski Antineoplastons: Progression-Free Survival Rate (PFS): Protocol – BT-11 BRAINSTEM GLIOMAS and multicentric tumors (MBSG) (Pg. 466)
——————————————————————
10/2006..6 / 32% – 2 year Overall Survival Rate (OS): Burzynski Antineoplastons: Protocol – BT-11 BRAINSTEM GLIOMAS and multicentric tumors (MBSG) (Pg. 466)
——————————————————————
2003 – 4 / 33.3% – 2 year Survival: Burzynski Antineoplastons Protocol patients with recurrent diffuse intrinsic BRAIN STEM GLIOMA: BT-11 (Pgs. 91-92)
——————————————————————
3/2006 – 39% – 2 year Overall Survival: Burzynski Antineoplastons: Patients with high-grade, recurrent and progressive BRAINSTEM GLIOMAS (BSG) (Pgs. 40 + 44-45)
——————————————————————
4/2007 – 8 / 40% – 2 year Overall Survival (OS): Burzynski Antineoplastons (ANP): Protocol – newly diagnosed diffuse, intrinsic BRAINSTEM GLIOMAs (NDBSG) BT-11 (Pg. 206)
——————————————————————
2004 – 42% – 2 year Patients (Surviving) Survival: Burzynski Antineoplastons: 6/1/2003 Protocol – BRAIN STEM GLIOMA (Pgs. 52-53)
——————————————————————
10/2004..13 / 45% – 2 year Overall Survival (Survival: Special Exception (SE)) Burzynski Antineoplastons: Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG) (Pg. 386)
——————————————————————
2006 – 14 / 46.7% – 2 year Overall Survival (OS) (%) – Efficacy: Burzynski Antineoplastons (ANP): Treatments for Astrocytic Tumors – recurrent and progressive tumor: Treatment of diffuse, intrinsic BRAINSTEM GLIOMA in children (Pg. 172)
——————————————————————
2006 – 30 / 46.7% – 2 year Overall Survival (OS) (%) – Efficacy: next best traditional standard of care study (Pg. 172)
——————————————————————
7/2005 – 5 / 50% – 2 year Overall Survival: Burzynski Antineoplastons: children less than 4 years old with inoperable BRAIN STEM GLIOMAs (BSG) BT-11 (study and Special Exception (SE)) (Pg. 300)
——————————————————————
2006 – 6 / 60% – 2 year Overall Survival (OS) (%) – Efficacy: Burzynski Antineoplastons (ANP) – recurrent and progressive (RPS) tumors in children aged <4y: children less than 4 years old with inoperable BRAIN STEM GLIOMAS (Pg. 172) 2005
——————————————————————
2006 – 6 / 60% – 2-year Survival rate: Burzynski Antineoplastons (ANP) – children aged <4 years diagnosed with diffuse intrinsic BRAIN STEM GLIOMA (DBSG) treated with ANP (Pg. 173) 2005
� � � � � � � � � � � � � � � � �
======================================
2+ YEARS PATIENTS SURVIVED
======================================
� � � � � � � � � � � � � � � � �
======================================
3/2006 – 2+ years – Most Patients with Newly Diagnosed High-Grade BRAIN STEM GLIOMAS (HBSG) don’t Survive more than: (Pgs. 40 + 45-46)
——————————————————————
2006 – 12 / >40% – 2+ year patients survived Burzynski Antineoplastons (ANP) recurrent and progressive diffuse intrinsic BRAINSTEM GLIOMA (DBSG) (Pg. 173)
======================================
� � � � � � � � � � � � � � � � �
======================================
3 YEAR OVERALL SURVIVAL
======================================
� � � � � � � � � � � � � � � � �
======================================
[9] .9/15/1994 – 7 / 11% – 3 years Overall Survival
======================================
� � � � � � � � � � � � � � � � �
======================================
4+ YEARS FROM START OF TREATMENT
======================================
� � � � � � � � � � � � � � � � �
======================================
2003 – 4+ years – 1 alive – From start of Treatment: Burzynski Antineoplastons Protocol patients with recurrent diffuse intrinsic BRAIN STEM GLIOMA: BT-11 (Pgs. 91-92)
======================================
� � � � � � � � � � � � � � � � �
======================================
LONG TERM SURVIVORS
======================================
� � � � � � � � � � � � � � � � �
======================================
2003 – 5+ years – 1 alive – Burzynski Antineoplastons: From start of Treatment: Protocol patients with recurrent diffuse intrinsic BRAIN STEM GLIOMA: BT-11 (Pgs. 91-92)
——————————————————————
[7] 3/15/1999 – 0% – 5 year Overall Survival (OS): standard radiation therapy in combination with chemotherapy (RAT) (Mandell et al.) (6/1992–10/1997) children with newly diagnosed diffuse intrinsic BRAIN STEM TUMORS: results of pediatric oncology group
——————————————————————
[6] .9/15/1999 – 5 / 15% – long term survivors who remained in continuous remission after mean follow-up period of 79 months {6 years 7 months} (46–104 months [3 years 10 months – 8 years 8 months])
——————————————————————
10/2006..3 / 16% – 5 year Overall Survival Rate (OS): Burzynski Antineoplastons: Protocol – BT-11 BRAINSTEM GLIOMAS and multicentric tumors (MBSG) (Pg. 466)
——————————————————————
10/2004..5 / 16% – 5 years: Burzynski Antineoplastons: Overall Survival (Survival: Special Exception (SE)) Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG): Special Exception (SE) (Pg. 386)
——————————————————————
7/2005 – 2 / 20% – 5 year Overall Survival: Burzynski Antineoplastons: children less than 4 years old with inoperable BRAIN STEM GLIOMAs (BSG) BT-11 (study and Special Exception (SE)) (Pg. 300)
——————————————————————
2005 – 2 / 20% – 5 year Overall Survival (OS) (%) – Efficacy: Burzynski Antineoplastons (ANP) – recurrent and progressive (RPS) tumors in children aged <4y: children less than 4 years old with inoperable BRAIN STEM GLIOMAS 2006 (Pg. 172)
——————————————————————
2005 – 2 / 20% – 5-year Survival rate: 2006 Burzynski Antineoplastons (ANP) – children aged <4 years diagnosed with diffuse intrinsic BRAIN STEM GLIOMA (DBSG) treated with ANP (Pg. 173)
——————————————————————
3/2006 – 22% – Burzynski Antineoplastons 5 year Overall Survival: Patients with high-grade, recurrent and progressive BRAINSTEM GLIOMAS (BSG) (Pgs. 40 + 44-45)
——————————————————————
10/2004..7 / 24% – 5 years: Burzynski Antineoplastons: Overall Survival (Survival: Special Exception (SE)) Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG) (Pg. 386)
——————————————————————
4/2007 – 6 / 30% – 5 year Overall Survival (OS): Burzynski Antineoplastons ((ANP): Protocol – newly diagnosed diffuse, intrinsic BRAINSTEM GLIOMAs (NDBSG) BT-11 (Pg. 206)
——————————————————————
2005 – 9 / 30% – 5 year Overall Survival (OS) (%) – Efficacy: Burzynski Antineoplastons (ANP): Treatments for Astrocytic Tumors – recurrent and progressive tumor: Treatment of diffuse, intrinsic BRAINSTEM GLIOMA in children 2006 (Pg. 172)
——————————————————————
2005 – 9 / 30% – 5+ year patients survived Burzynski Antineoplastons (ANP) recurrent and progressive diffuse intrinsic BRAINSTEM GLIOMA (DBSG) 2006 (Pg. 173)
——————————————————————
2003 – 2 / 17% – 5+ years Alive and Tumor Free since Initial Diagnosis: Burzynski Antineoplastons: Protocol patients with recurrent diffuse intrinsic BRAIN STEM GLIOMA: BT-11 (Pgs. 91-92)
——————————————————————
9 / 30% – 5+ year patients survived 2006 Burzynski Antineoplastons (ANP) recurrent and progressive diffuse intrinsic BRAINSTEM GLIOMA (DBSG) (Pgs. 172-173)
======================================
� � � � � � � � � � � � � � � � �
======================================
SURVIVAL
======================================
� � � � � � � � � � � � � � � � �
======================================
[2] 5/1/2010 – 6.9 months – Progression-Free Survival (PFS)
——————————————————————
[5] .10/21/2002 – 8 months – Overall Median Survival
——————————————————————
[3] 2/2008 – 9 months (3–36 months [3 years]) – Median Survival (MS)
——————————————————————
[2] 5/1/2010 – 9.15 months – Median Overall Survival
——————————————————————
[1] 4/2011 – 9.6 months – Median Time to Death
——————————————————————
[4] 1/1/2005 – 12 months (1 year) – Median Survival (MS)
——————————————————————
[6] .9/15/1999 – 12 months (1 year) – Overall Survival (5–104+ months [5 months – 8 years 8+ months])
======================================
2 YEARS 2.3 MONTHS MEDIAN SURVIVAL TIME (MST)
======================================
� � � � � � � � � � � � � � � � �
======================================
2006 – 26.3 months (2 years 2.3 months) – Burzynski Antineoplastons (ANP) – Median Survival Time (MST): recurrent and progressive (RPS) tumors in children aged <4y: children less than 4 years old with inoperable BRAIN STEM GLIOMAS 2005 (Pg. 172)
======================================
� � � � � � � � � � � � � � � � �
======================================
3 YEARS MEDIAN OVERALL SURVIVAL FROM DIAGNOSIS (OSD)
======================================
� � � � � � � � � � � � � � � � �
======================================
2004 – 3 years – with treatment, may approach (Pg. 53)
——————————————————————
2004 – 3 years – Burzynski Antineoplastons Median Overall Survival from Diagnosis (OSD): 6/1/2003 Protocol – HIGH-GRADE GLIOMA (Pg. 53)
======================================
� � � � � � � � � � � � � � � � �
======================================
5+ YEARS SURVIVAL
======================================
� � � � � � � � � � � � � � � � �
======================================
3/2006 – 5+ years – Burzynski Antineoplastons: Survival in recurrent diffuse intrinsic GLIOBLASTOMAS and anaplastic ASTROCYTOMAS of the BRAINSTEM in a small group of Patients: BRAINSTEM GLIOMA (BSG) Patient with GLIOBLASTOMA (Pgs. 40 + 44-45)
======================================
� � � � � � � � � � � � � � � � �
======================================
6+ YEARS MAXIMUM SURVIVAL (MS)
======================================
� � � � � � � � � � � � � � � � �
======================================
7/2005 – 6+ years – Burzynski Antineoplastons: Maximum Survival (MS): children less than 4 years old with inoperable BRAIN STEM GLIOMAs (BSG) BT-11 (study and Special Exception (SE)) (Pg. 300)
——————————————————————
6+ years – Burzynski Antineoplastons Patient with recurrent, diffuse, intrinsic GLIOBLASTOMA MULTIFORME (GBM)
======================================
� � � � � � � � � � � � � � � � �
======================================
6.3 YEARS MEDIAN OVERALL SURVIVAL FROM DIAGNOSIS (OSD)
======================================
� � � � � � � � � � � � � � � � �
======================================
2004 – 6.3 years – Burzynski Antineoplastons: Median Overall Survival from Diagnosis (OSD): 6/1/2003 Protocols – LOW-GRADE GLIOMA IN CHILDREN (Pg. 50)
======================================
� � � � � � � � � � � � � � � � �
======================================
7+ YEARS LONGEST / MAXIMUM SURVIVAL
======================================
� � � � � � � � � � � � � � � � �
======================================
3/2004 – 7+ years – Burzynski Antineoplastons: Longest Survival (the Patients are currently alive): Protocol – subgroup very difficult to treat recurrent diffuse intrinsic BRAIN STEM GLIOMA (Pg. 52)
——————————————————————
2006 – 7+ years – Burzynski Antineoplastons (ANP) – Maximum Survival (MS): children aged <4 years diagnosed with diffuse intrinsic BRAIN STEM GLIOMA (DBSG) treated with ANP (Pg. 173)
======================================
� � � � � � � � � � � � � � � � �
======================================
7.5+ YEARS MAXIMUM SURVIVAL (MS)
======================================
� � � � � � � � � � � � � � � � �
======================================
2004 – 7.5+ years – Burzynski Antineoplastons Maximum Survival (MS): 6/1/2003 Protocol – BT-11 BRAIN STEM GLIOMA (Pg. 51)
======================================
� � � � � � � � � � � � � � � � �
======================================
9+ YEARS MAXIMUM SURVIVAL (MS)
======================================
� � � � � � � � � � � � � � � � �
======================================
10/2006 – 9+ years – Burzynski Antineoplastons: Maximum Survival Rate: Protocol – BT-11 BRAINSTEM GLIOMAS and multicentric tumors (MBSG) (Pg. 466)
======================================
� � � � � � � � � � � � � � � � �
======================================
11 YEARS MAXIMUM SURVIVAL (MS)
======================================
� � � � � � � � � � � � � � � � �
======================================
10/2004..11 years – Burzynski Antineoplastons: Maximum Survival: Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG): Special Exception (SE): (high-grade diffuse intrinsic BRAIN STEM GLIOMA (DBSG) recurrent after radiation and chemotherapy) (Pg. 386)
======================================
� � � � � � � � � � � � � � � � �
======================================
12.5+ YEARS MAXIMUM SURVIVAL (MS)
======================================
� � � � � � � � � � � � � � � � �
======================================
2004 – 12.5+ years – Burzynski Antineoplastons: Maximum Survival (MS): 6/1/2003 Protocol – HIGH-GRADE GLIOMA (Pg. 53)
======================================
� � � � � � � � � � � � � � � � �
======================================
15.5+ YEARS MAXIMUM SURVIVAL (MS)
======================================
� � � � � � � � � � � � � � � � �
======================================
10/2004 – 15.5+ years – Burzynski Antineoplastons: Maximum Survival: Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG): (high-grade diffuse intrinsic BRAIN STEM GLIOMA (DBSG) recurrent after radiation and chemotherapy) (Pg. 386)
======================================
� � � � � � � � � � � � � � � � �
======================================
17+ YEARS MAXIMUM SURVIVAL (MS)
======================================
� � � � � � � � � � � � � � � � �
======================================
3/2006 – 17+ years (approaching 18 years) – Burzynski Antineoplastons: BRAINSTEM GLIOMA (BSG) Maximum Survival for Patient with recurrent, diffuse, intrinsic anaplastic ASTROCYTOMA (Pgs. 40 + 44-45)
======================================
� � � � � � � � � � � � � � � � �
======================================
Burzynski: BRAINSTEM GLIOMAs (DBSG):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/07/31/burzynski-brainstem-gliomas-dbsg/
======================================
References:
======================================
[1] 4/2011 – children with newly diagnosed diffuse intrinsic pontine gliomas
======================================
Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children’s Oncology Group
http://www.ncbi.nlm.nih.gov/pubmed/21345842/
Neuro Oncol. 2011 Apr;13(4):410-6. doi: 10.1093/neuonc/noq205. Epub 2011 Feb.22
http://www.ncbi.nlm.nih.gov/m/pubmed/21345842/
Neuro-oncology 2011 Apr; 13(4):410-6
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064697/
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064697/pdf/noq205.pdf
the Children’s Oncology Group
http://m.neuro-oncology.oxfordjournals.org/content/13/4/410.long?view=long&pmid=21345842
open-label phase II study (ACNS0126)
7/6/2004-9/6/2005
======================================
[2] 5/1/2010 – Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
======================================
Prospective Evaluation of Radiotherapy With Concurrent and Adjuvant Temozolomide in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
http://www.ncbi.nlm.nih.gov/pubmed/19647954/
Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):113-8. doi: 10.1016/j.ijrobp.2009.04.031. Epub 2009 Aug 3
http://www.ncbi.nlm.nih.gov/m/pubmed/19647954/
International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 1 , Pages 113-118, 1 May 2010
http://www.redjournal.org/article/S0360-3016(09)00597-5/abstract
published online 03 August 2009
Department of Radiation Oncology, Tata Memorial Centre, Mumbai, India
Presented at the Eighth Congress of the European Association for Neuro-Oncology, Barcelona, Spain, September 12–14, 2008
3/2005-11/2006
======================================
[3] 2/2008 – children with diffuse intrinsic brain stem glioma
======================================
Research Article
Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: A Children’s Oncology Group phase II study
http://www.ncbi.nlm.nih.gov/pubmed/17278121/
Pediatr Blood Cancer. 2008 Feb;50(2):227-30
http://www.ncbi.nlm.nih.gov/m/pubmed/17278121/
Pediatr Blood Cancer 2008;50:227–230
http://onlinelibrary.wiley.com/doi/10.1002/pbc.21154/abstract
Pediatric Blood & Cancer
Volume 50, Issue 2, pages 227–230, February 2008
http://onlinelibrary.wiley.com/doi/10.1002/pbc.21154/abstract;jsessionid=1C9E44F96D6558468F0D7EB45D50FE23.d04t03
Pediatric Blood & Cancer
Volume 50, Issue 2, Article first published online: 2 FEB 2007
http://onlinelibrary.wiley.com/doi/10.1002/pbc.21154/full
The Pediatric Oncology Group (POG, now part of the Children’s Oncology Group)
http://onlinelibrary.wiley.com/doi/10.1002/pbc.21154/pdf
DOI 10.1002/pbc.21154
http://radonc.ucsd.edu/patient-info/treatment-options/cancer-types/pediatric-cancers/Documents/Pediatric-Paper-04.pdf
University of Rochester Medical Center, Rochester, New York, USA
======================================
[4] 1/1/2005 – newly diagnosed diffuse brainstem glioma in children
======================================
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children:
results of a multiinstitutional study (SJHG-98)
http://www.ncbi.nlm.nih.gov/pubmed/15565574
Cancer. 2005 Jan 1;103(1):133-9.
http://www.ncbi.nlm.nih.gov/m/pubmed/15565574
Cancer 103, 133-139
http://onlinelibrary.wiley.com/doi/10.1002/cncr.20741/abstract;jsessionid=6717837591CCC8FCBD8E46163808E221.d03t01
Cancer
Volume 103, Issue 1, pages 133–139, 1 January 2005
http://onlinelibrary.wiley.com/doi/10.1002/cncr.20741/full
Article first published online: 24 NOV 2004
References:
http://onlinelibrary.wiley.com/doi/10.1002/cncr.20741/references
Cited By:
http://onlinelibrary.wiley.com/doi/10.1002/cncr.20741/citedby
DOI: 10.1002/cncr.20741
Department of Hematology-Oncology, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
======================================
[5] .10/21/2002 – paediatric pontine glioma
======================================
Treatment of paediatric pontine glioma with oral trophosphamide and etoposide
http://www.ncbi.nlm.nih.gov/pubmed/12434281/
Br J Cancer. 2002 Oct 21;87(9):945-9
http://www.ncbi.nlm.nih.gov/m/pubmed/12434281/
British Journal of Cancer (2002) 87, 945–949. doi:10.1038/sj.bjc.6600552
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364312/
Published online 21 October 2002
http://www.nature.com/bjc/journal/v87/n9/full/6600552a.html
St. Hedwigs Klinik, Hämato/Onkologie, Steinmetzstr. 1–3, Regensburg, Germany
http://www.nature.com/bjc/journal/v87/n9/pdf/6600552a.pdf
======================================
[6] .9/15/1999 – brainstem gliomas
======================================
A Phase I/II study of carboplatin combined with hyperfractionated radiotherapy for
brainstem gliomas

http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0142(19990915)86:6%3C1064::AID-CNCR24%3E3.0.CO;2-1/full
Cancer 1999;86:1064–9
1999 American Cancer Society
Cancer
Volume 86, Issue 6, pages 1064–1069, 15 September 1999
Article first published online: 20 NOV 2000
DOI: 10.1002/(SICI)1097-0142(19990915)86:63.0.CO;2-1
======================================
[7] 3/15/1999 children with newly diagnosed diffuse intrinsic brainstem tumors
======================================
There is no role for hyperfractionated radiotherapy in the management of
children with newly diagnosed diffuse intrinsic brainstem tumors
: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy
http://www.ncbi.nlm.nih.gov/pubmed/10192340/
Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):959-64
http://www.ncbi.nlm.nih.gov/m/pubmed/10192340/
International Journal of Radiation Oncology * Biology * Physics
Volume 43, Issue 5 , Pages 959-964, 15 March 1999
http://www.redjournal.org/article/S0360-3016(98)00501-X/abstract
Department of Radiation Oncology, Mount Sinai Medical Center, New York, NY 10029-6574, USA
======================================
[8] 1/1998 – children with newly diagnosed diffuse pontine gliomas
======================================
Carboplatin and etoposide with hyperfractionated radiotherapy in children with newly diagnosed diffuse pontine gliomas: a phase I/II study
http://www.ncbi.nlm.nih.gov/pubmed/9371386/
Med Pediatr Oncol. 1998 Jan;30(1):28-33
http://www.ncbi.nlm.nih.gov/m/pubmed/9371386/
Medical and Pediatric Oncology
Volume 30, Issue 1, pages 28–33, January 1998
http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1096-911X(199801)30:13.0.CO;2-2/abstract;jsessionid=94E4BFEF2606B89ADDD9682528353D47.d03t02
Article first published online: 7 DEC 1998
http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1096-911X(199801)30:13.0.CO;2-2/pdf
DOI: 10.1002/(SICI)1096-911X(199801)30:13.0.CO;2-2
Department of Hematology-Oncology, St. Jude Children’s Research Hospital, University of Tennessee, Memphis, USA
Pediatric Oncology
======================================
[9] .9/15/1994 – children with brain stem gliomas
======================================
Outcome of children with brain stem gliomas after treatment with 7800 cGy of hyperfractionated radiotherapy. A Childrens Cancer Group Phase I/II Trial
http://www.ncbi.nlm.nih.gov/pubmed/8082086/
Cancer. 1994 Sep 15;74(6):1827-34
http://www.ncbi.nlm.nih.gov/m/pubmed/8082086/
Department of Neurology, Children’s National Medical Center, Washington, DC
======================================
� � � � � � � � � � � � � � � � �
======================================
The Burzynski Skeptics:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/08/18/the-burzynski-skeptics/
======================================
Perfessor Robert J. (Bob) Blaskiewicz Blatherskitewicz:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/07/31/the-burzynski-b-s-app/
======================================
Bob Blaskiewicz (Blatherskitewicz), Faux Skeptic Exposed!:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/06/07/bob-blaskiewicz-blatherskitewicz-faux-skeptic-exposed/
======================================
Critiquing the #SkepticCanary: “The Skeptics™” (SkeptiCowards©) Bob Blatherskitewicz and the so-called, “self-proclaimed” “CANCER RESEARCHER”:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/06/03/critiquing-the-skepticcanary-the-skeptics-skepticowards-bob-blatherskitewicz-and-the-so-called-self-proclaimed-cancer-researcher/
======================================
Critiquing Bob Blaskiewicz (#Burzynski Cancer is Serious Business, Part II):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/03/26/critiquing-bob-blaskiewicz-burzynski-cancer-is-serious-business-part-ii/
======================================
My Critique of Bob Blaskiewicz (Colorado Public Television – PBS CPT12):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/03/26/my-critique-of-bob-blaskiewicz-colorado-public-television-pbs-cpt12/
======================================
“The Skeptics” (Burzynski: Cancer is Serious Business, Part II):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/03/24/the-skeptics/
======================================
� � � � � � � � � � � � � � � � �